1,1-二甲基-4-苯基-2,3,5,6-四氢吡嗪 | 114-28-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1,1-二甲基-4-苯基-2,3,5,6-四氢吡嗪
• 英文名称: Dimethylphenylpiperazinium
• 英文别名: 1,1-dimethyl-4-phenylpiperazin-1-ium
• CAS: 114-28-3
• 化学式: C12H19N2+
• 分子量: 191.29
• InChiKey: MKGIQRNAGSSHRV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2933599090

文献信息

• Pharmaceutical use of compounds which bind to a mammalian "trace amine" receptor
  申请人：Oregon Health & Science University

  公开号：EP1568770A2

  公开（公告）日：2005-08-31

  The present invention relates to novel mammalian biogenic amine receptor proteins and genes that encode such proteins. The invention provides methods for screening compounds in vitro that are capable of binding to the mammalian trace amine receptor proteins of the invention, and further characterizing the binding properties of such compounds and functional consequences thereof in comparison with known trace amine receptor agonists and antagonists. Improved methods of pharmacological screening are provided thereby.

  本发明涉及新型哺乳动物生物胺受体蛋白和编码此类蛋白的基因。本发明提供了体外筛选能与本发明的哺乳动物痕量胺受体蛋白结合的化合物的方法，并与已知的痕量胺受体激动剂和拮抗剂相比，进一步表征了这些化合物的结合特性及其功能后果。由此提供了改进的药理学筛选方法。
• MRI-guided intraarterial catheter-based method for predicting territory of local blood brain barrier opening
  申请人：The Johns Hopkins University

  公开号：US10478120B2

  公开（公告）日：2019-11-19

  The present invention provides a method of administering a therapeutic agent directly to the brain parenchym through a compromised region of the blood-brain barrier in a subject having a brain disorder, that involves first disrupting the blood-brain barrier (BBB) at an isolated region by locally administering an effective amount of a hyperosmolar agent at said region using a catheter, followed by administering a therapeutically effective amount of a therapeutic agent. The step of disrupting the BBB is carried out with non-invasive MR (magnetic resonance) imaging with a contrast agent to visualize local parenchymal transcatheter perfusion at said isolated BBB region thereby indicating that the BBB region is compromised. The method of the invention allows for highly precise drug delivery to the brain through blood brain barrier disruption at specifically controlled regions.

  本发明提供了一种通过血脑屏障受损区域直接向患有脑部疾病的受试者的脑实质施用治疗剂的方法，该方法包括首先通过使用导管在所述区域局部施用有效量的高渗剂来破坏隔离区域的血脑屏障（BBB），然后施用治疗有效量的治疗剂。破坏 BBB 的步骤通过使用造影剂的非侵入性 MR（磁共振）成像进行，以观察所述隔离 BBB 区域的局部实质经导管灌注，从而表明 BBB 区域受到破坏。本发明的方法可通过在特定受控区域破坏血脑屏障向大脑高度精确地输送药物。
• Chemically amplified resist composition and patterning process
  申请人：SHIN-ETSU CHEMICAL CO., LTD.

  公开号：US10698314B2

  公开（公告）日：2020-06-30

  A chemically amplified resist composition comprising a quencher containing a quaternary ammonium iodide, dibromoiodide, bromodiiodide or triiodide, and an acid generator exhibits a sensitizing effect and an acid diffusion suppressing effect and forms a pattern having improved resolution, LWR and CDU.

  一种化学放大抗蚀剂组合物由含有季铵碘化物、二溴碘化物、溴碘化物或三碘化物的淬灭剂和酸发生器组成，具有敏化效果和抑制酸扩散的效果，并能形成具有更高分辨率、更低辐射和 CDU 的图案。
• VARIANT HUMAN ALPHA7 ACETYLCHOLINE RECEPTOR SUBNIT, AND METHODS OF PROD0U0CTION AND USES THEREOF
  申请人：——

  公开号：US20010006796A1

  公开（公告）日：2001-07-05

  A variant human U7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human &agr;7 nAChR. Nucleic acid molecules encoding the variant human &agr;7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.

  提供了一种变体人 U7 烟碱乙酰胆碱受体（nAChR）多肽，其中变体包含野生型人 &agr;7 nAChR 的缬氨酸-274 位上的氨基酸替代。还提供了编码变体人 &agr;7 nAChR 的核酸分子、载体和含有这种核酸分子的宿主细胞。此外，还提供了生产变体的方法，以及使用这种变体筛选化合物在 nAChR 上的活性的方法。
• Variant human alpha7 acetylcholine receptor subunit, and methods of production and use thereof
  申请人：——

  公开号：US20030073161A1

  公开（公告）日：2003-04-17

  A variant human &agr;7 nicotinic acetylcholine receptor (nAChR) polypeptide is provided wherein the variant contains an amino acid substitution at the valine-274 position of the wild-type human &agr;7 nAChR. Nucleic acid molecules encoding the variant human &agr;7 nAChR, vectors and host cells containing such nucleic acid molecules are also provided. In addition, methods are provided for producing the variant as are methods of using such variants for screening compounds for activity at the nAChR.

  提供了一种变体人 &agr;7 烟碱乙酰胆碱受体（nAChR）多肽，其中变体包含野生型人 &agr;7 nAChR 的缬氨酸-274 位上的氨基酸替换。还提供了编码变体人 &agr;7 nAChR 的核酸分子、载体和含有这种核酸分子的宿主细胞。此外，还提供了生产变体的方法，以及使用这种变体筛选化合物在 nAChR 上活性的方法。